Content deleted Content added
sp |
m remove href oddities |
||
Line 346:
* [[Telbivudine]] is effective but not recommended as first-line treatment; as compared to entecavir, it is both less potent and more resistance prone.<ref name="Harrison's Principles, chapter 362 (Chronic)" />
* [[Tenofovir disoproxil|Tenofovir]] is a nucleotide analogue and an antiretroviral drug that is also used to treat HIV infection.<ref name="Harrison's Principles, chapter 362 (Chronic)" /> It is preferred to adefovir both in lamivudine-resistant patients and as initial treatment since it is both more potent and less likely to develop resistance.<ref name="Harrison's Principles, chapter 362 (Chronic)" />
First-line treatments currently used include PEG IFN, entecavir, and tenofovir, subject to patient and physician preference.<ref name="Harrison's Principles, chapter 362 (Chronic)" /> Treatment initiation is guided by recommendations issued by The American Association for the Study of Liver Diseases (AASLD) and the European Association for the Study of the Liver (EASL) and is based on detectable viral levels, [[HBeAg]] positive or negative status, [[Alanine transaminase|ALT]] levels, and in certain cases, family history of HCC and liver biopsy.<ref name="Harrison's Principles, chapter 362 (Chronic)" /> In patients with compensated cirrhosis, treatment is recommended regardless of HBeAg status or ALT level, but recommendations differ regarding HBV DNA levels; AASLD recommends treating at DNA levels detectable above 2x10<sup
=== Hepatitis C ===
| |||